News|Articles|April 8, 2025

Pharma Pulse 4/8/25: Sustainability in Clinical Trials, Unpacking the Truth Behind GLP-1 Myths & more

The latest news for pharma industry insiders.

Sustainability in Clinical Trials: The Pistoia Alliance’s Initiative to Assess Carbon Footprint

In a recent video interview with Applied Clinical Trials, Theirry Escudier, Portfolio Lead, Pistoia Alliance, discussed the alliance’s newest initiative to assess the carbon footprint of clinical trials. The initiative aims to answer whether decentralized clinical trials positively or negatively impact carbon footprints. Escudier also discussed how clinical research stakeholders are slowly beginning to adopt more sustainability practices, focusing on reducing waste and costs.

Unpacking the Truth Behind GLP-1 Myths

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to lifestyle changes and long-term effectiveness—to help patients and providers separate hype from reality.

Banks Postpone Loans as Tariffs Stoke Fears of ‘Hung’ Debt

Wall Street lenders are postponing leveraged-finance deals as investors shy away from risky transactions while global markets convulse in the wake of US President Donald Trump’s sweeping tariffs.

Hello Heart Unveils Connected Pill Box to Radically Improve Medication Adherence

Hello Heart has introduced Hello Heart Pill Box, a proprietary smart pill box designed to improve medication adherence. This addition to Hello Heart’s suite of heart health tools, including its blood pressure monitor and mobile app, addresses one of the most critical factors of cardiovascular care management.

Karger Publishers on LinkedIn

Building trust between HCPs and patients is key for innovation in healthcare.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.